Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $34 | $28 | $43 | $60 |
| Short-Term Investments | $337 | $455 | $394 | $280 |
| Receivables | $5 | $0 | $0 | $3 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $10 | $14 | $15 | $8 |
| Total Curr. Assets | $386 | $497 | $452 | $351 |
| Property Plant & Equip (Net) | $37 | $42 | $50 | $53 |
| Goodwill | $0 | $4 | $4 | $4 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $3 | $24 | $40 |
| Tax Assets | $0 | $10 | $14 | $18 |
| Other NC Assets | $7 | $7 | $10 | $7 |
| Total NC Assets | $44 | $65 | $102 | $121 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $430 | $562 | $553 | $472 |
| Liabilities | – | – | – | – |
| Payables | $7 | $15 | $11 | $12 |
| Short-Term Debt | $3 | $3 | $2 | $1 |
| Tax Payable | $0 | $0 | $0 | $1 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $42 | $51 | $43 | $30 |
| Total Curr. Liab. | $53 | $69 | $57 | $44 |
| LT Debt | $40 | $43 | $45 | $44 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $10 | $15 | $19 |
| Other NC Liab. | $1 | $2 | $3 | $0 |
| Total NC Liab. | $40 | $55 | $63 | $64 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $43 | $43 | $45 | $44 |
| Total Liabilities | $93 | $125 | $119 | $108 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,054 | -$889 | -$596 | -$360 |
| AOCI | $1 | $2 | -$1 | -$0 |
| Other Equity | $1,391 | $1,324 | $1,031 | $724 |
| Total Equity | $337 | $437 | $434 | $364 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $1 |
| Total Liab. & Tot. Equity | $430 | $562 | $553 | $472 |
| Net Debt | $9 | $18 | $4 | -$14 |